drugset / Trial / NCT02706470

Use of Cyclosporin A for the Treatment of Recurrent Miscarriage

NCT02706470

Phase 2/3 Unknown 384 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Cyclosporin A (CsA) - an immunosuppressant drug - in early pregnancy will reduce the risk of miscarriage in women who had a history of unexplained recurrent miscarriages, as compared with that treated with Dydrogesterone-an active comparator. The hypothesis is based on the evidence found in vitro and in vivo experiments that CsA can induce maternal-fetal tolerance so that it may reduce the risk of miscarriage.

Timeline

Start
2016-05
Primary completion
2018-02
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 50 mg Oral
Subject Cyclosporine Peptide 75 mg Oral
Comparator Dydrogesterone Other / unclassified 10 mg Oral